中文摘要：

Hepatocellular 癌(HCC ) 是世界范围的癌症相关的死亡的一个领先的原因。在药品治疗以后的 HCC 的复发当前是一个主要障碍。有不同预后的病人的子集的鉴定提供一个机会定制治疗学的途径以及为指向的治疗与特定的亚显型选择病人。因此，表示介绍改进 HCC 预后的预言的基因的发展为 HCC 管理是重要的。尽管几基因签名为 HCC 预后的预言被评估了，这些签名的预兆的力量上没有一致。使用系统的途径评估这些签名并且把他们与 clinicopathologic 信息相结合可以提供 HCC 预后的更多的精确预言。最近， Villanueva 等[13 ] 开发了在肿瘤和邻近的纸巾合并基因表示模式预言 HCC 的一个合成预示的模型复发。在这评论，我们在使用基因签名预言 HCC 预后总结当前的进步，并且讨论重要性，存在这块地里的问题和未来研究方向。

英文摘要：

Hepatocellular carcinoma （HCC） is a leading cause of cancer-related death worldwide.The recurrence of HCC after curative treatments is currently a major hurdle.Identification of subsets of patients with distinct prognosis provides an opportunity to tailor therapeutic approaches as well as to select the patients with specific sub-phenotypes for targeted therapy.Thus,the development of gene expression profiles to improve the prediction of HCC prognosis is important for HCC management.Although several gene signatures have been evaluated for the prediction of HCC prognosis,there is no consensus on the predictive power of these signatures.Using systematic approaches to evaluate these signatures and combine them with clinicopathologic information may provide more accurate prediction of HCC prognosis.Recently,Villanueva et al developed a composite prognostic model incorporating gene expression patterns in both tumor and adjacent tissues to predict HCC recurrence.In this commentary,we summarize the current progress in using gene signatures to predict HCC prognosis,and discuss the importance,existing issues and future research directions in this field.